Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC (formerly FINSBURY WORLDWIDE PHARMACEUTICAL   
                                  TRUST PLC)                                   

      Interim Management Statement - 3 months to 30 June 2010 (unaudited)      

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, 
biotechnology and related companies in the healthcare sector with the objective
of achieving a high level of capital growth.

The 3 month period ended 30 June 2010 was a challenging one for the Company due
in part to mixed performance from large pharmaceutical companies such as
Novartis, which performed well following positive newsflow regarding its
treatment for multiple sclerosis, and Pfizer whose performance lagged due, in
part, to the unexpected stoppage of an experimental osteoarthritis drug in late
stage development. Over the three-month period, the Company's fully diluted net
asset value per share fell by 5.6% and the share price by 7.7%, compared to a
fall of 8.6% in the Company's benchmark, the DataStream World Pharmaceutical
and Biotechnology Index measured in sterling terms on a total return basis.

During this period a total of 1,637,733 shares were repurchased to be held in
treasury at a cost of £10.9m (including expenses). Since the period end, to 4
August 2010, no shares have been repurchased by the Company. On 27 July 2010
the Company cancelled all of the 7,877,149 shares held in treasury. There are
currently no shares held in treasury.

Also, during the three month period and up to 4 August 2010, a total of 686,893
new shares were issued, raising £4.2m of additional funds for the Company, as a
result of holders of subscription shares exercising their subscription rights.

In the period from 30 June 2010 to 4 August 2010, the Company's fully diluted
net asset value per share rose by 1.3% and the share price fell by 0.3%
compared to a fall of 1.1% in the Company's benchmark.

At the Company's Annual General Meeting, held on 15 July 2010, all of the
resolutions were passed. These included resolutions to amend the Company's
investment policy to that of a broader healthcare sector remit, a change to its
benchmark and also to change the Company's name.

The Company paid an increased interim dividend of 8.5p per share (2009: 5.0p
per share) on 26 July 2010.

Trust Characteristics

                            30 June 2010             31 March 2010             
                                                                               
Number of holdings          44                       44                        
                                                                               
Net assets (£m)             307.5                    341.9                     
                                                                               
Net yield                   1.3%                     0.7%                      
                                                                               
Gearing (AIC basis)         107                      111                       
                                                                               
Share price (p)             639.00                   701.50                    
                                                                               
NAV (p) -undiluted          715.42                   771.27                    
                                                                               
NAV (p) diluted: sub shares 698.33                   744.75                    
                                                                               
NAV (p) - fully diluted for 690.48                   740.22                    
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
(Discount)/premium          (10.7%)                  (9.0%)                    
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted - (8.5%)                   (5.8%)                    
sub shares)                                                                    
                                                                               
(Discount)/premium (fully   (7.5%)                   (5.2%)                    
diluted)                                                                       
                                                                               
Subscription share price    64.00                    98.00                     
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                                at 30 June 2010           at 31 March 2010     
                                                                               
Novartis                              8.3                       5.0            
                                                                               
Johnson & Johnson                     7.3                       6.9            
                                                                               
Pfizer                                7.2                       5.1            
                                                                               
Merck                                 7.1                       4.8            
                                                                               
Roche                                 6.9                       6.9            
                                                                               
Bristol-Myers Squibb                  5.1                       4.7            
                                                                               
Amgen                                 2.9                       2.8            
                                                                               
Sawai Pharmaceutical                  2.6                       2.1            
                                                                               
Hospira                               2.5                       2.1            
                                                                               
Genzyme                               2.5                       2.8            
                                                                               
                                     52.4                       43.2           

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                                at 30 June 2010           at 31 March 2010     
                                                                               
Large capitalisation                 74.8                       65.8           
                                                                               
Small capitalisation                 25.2                       34.2           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                               at 30 June 2010            at 31 March 2010     
                                                                               
North America                        63.3                       71.0           
                                                                               
Europe                               25.9                       17.9           
                                                                               
Israel                               0.0                        2.8            
                                                                               
Far East                             10.8                       8.3            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     -7.7%           +22.6%          +35.4%          +42.1%         
                                                                               
NAV Fully       -5.6%           +24.7%          +36.6%          +54.0%         
diluted                                                                        
                                                                               
Benchmark*      -8.6%           +20.4%          +22.6%          +35.1%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Reuters

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Subscription Shares - B3VMCB0

ISIN -

Shares - GB0003385308

Subscription Shares - GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

6 August 2010


  ND